- Home
- Shareholder and Investor Information
- Understanding RaQualia Pharma! RaQualia FAQ
- What are RaQualia’s strengths?
-

- Human resources
- A group of researchers with broad experiences and a solid record of achievements in developing medications
- A management team that understands the needs of global customers
- Portfolio
- Consistent creation of new development compounds
- Expansion of market potential by adding new target indications
- Improvement of the probability of commercialization by rapid confirmation of product concepts
- Infrastructure
- A comprehensive research support structure and the most advanced research facility
- Growth Potential
- The ability to produce two new development compounds per year
-

The foundation of RaQualia Pharma's business model is the Integrated Open Collaboration Network (IOCN). IOCN does not distinguish between external and internal company resources. All employees focus on innovation and, by cooperating with partners both inside and outside the company, make high and sustained productivity possible. RaQualia Pharma's core competence is to rapidly, efficiently, and effectively create research programs and development candidate compounds. We actively seek opportunities for partnership via licensing and joint development in all of these programs and at all research stages. This model is the driving force behind improving value for patients, our customers, investors and shareholders.
IOCN is based on trust with our partners. Building trust among our colleagues, in other words both within RaQualia and between RaQualia and companies, customers, partners and stakeholders, is the foundation.
-

RaQualia Pharma operates with a unique organizational structure. Our organization is flat and management comprises a single layer. Management and team members participate in decisionmaking, which allows for swift and cohesive decision making. There are no lines drawn between project teams: the power of the entire organization is focused on innovation.




